Grifols/$GRFS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Grifols
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Ticker
$GRFS
Sector
Primary listing
Employees
23,833
Headquarters
Website
Grifols Metrics
BasicAdvanced
$8.5B
18.10
$0.53
0.98
$0.14
1.48%
Price and volume
Market cap
$8.5B
Beta
0.98
52-week high
$11.14
52-week low
$6.19
Average daily volume
776K
Dividend rate
$0.14
Financial strength
Current ratio
2.636
Quick ratio
0.806
Long term debt to equity
119.998
Total debt to equity
126.869
Interest coverage (TTM)
2.56%
Profitability
EBITDA (TTM)
1,946.499
Gross margin (TTM)
39.64%
Net profit margin (TTM)
3.99%
Operating margin (TTM)
18.89%
Effective tax rate (TTM)
37.62%
Revenue per employee (TTM)
$365,140
Management effectiveness
Return on assets (TTM)
4.18%
Return on equity (TTM)
4.99%
Valuation
Price to earnings (TTM)
18.099
Price to revenue (TTM)
0.721
Price to book
1.4
Price to tangible book (TTM)
-1.63
Price to free cash flow (TTM)
7.722
Free cash flow yield (TTM)
12.95%
Free cash flow per share (TTM)
1.247
Dividend yield (TTM)
1.48%
Growth
Revenue change (TTM)
9.32%
Earnings per share change (TTM)
132.60%
3-year revenue growth (CAGR)
12.66%
10-year revenue growth (CAGR)
7.40%
3-year earnings per share growth (CAGR)
67.45%
10-year earnings per share growth (CAGR)
-4.84%
10-year dividend per share growth (CAGR)
-7.44%
What the Analysts think about Grifols
Analyst ratings (Buy, Hold, Sell) for Grifols stock.
Bulls say / Bears say
Grifols’ net profit almost tripled to €60 million in Q1 2025, boosted by a 7.4% year-on-year rise in net revenue to €1.79 billion, reinforcing confidence in its ability to achieve annual targets. (Reuters)
Shares jumped 13% after presenting its 2025 outlook, forecasting revenue between €7.5–7.6 billion and free cash flow of €350–400 million for the year, signaling strong investor support for its strategic plan. (Reuters)
On February 3, 2025, Grifols finalized the purchase of the remaining 14 plasma collection centers from ImmunoTek, securing full control of 28 centers in the U.S. and strengthening supply reliability and margin prospects. (SEC Form 20-F)
Despite recent refinancing efforts, Grifols’ net leverage remained high at 4.2x adjusted EBITDA as of H1 2025, which could limit its financial flexibility and heighten refinancing risks over the medium term. (Cinco Días)
Shares fell 8.7% over three trading days in early March after investors questioned the credibility of its long-term strategic plan, highlighting ongoing market concerns about management’s ability to deliver. (Cinco Días)
Legal disputes with short-seller Gotham City Research, including a U.S. court allowing Grifols’ defamation claim to proceed and a Spanish High Court investigation into Gotham, continue to present reputational risks and divert management attention from operations. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Grifols Financial Performance
Revenues and expenses
Grifols Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Grifols stock?
Grifols (GRFS) has a market cap of $8.5B as of September 17, 2025.
What is the P/E ratio for Grifols stock?
The price to earnings (P/E) ratio for Grifols (GRFS) stock is 18.1 as of September 17, 2025.
Does Grifols stock pay dividends?
Yes, the Grifols (GRFS) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $0.14238 and the yield is 1.48%. Grifols has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Grifols dividend payment date?
The next Grifols (GRFS) dividend payment date is unconfirmed.
What is the beta indicator for Grifols?
Grifols (GRFS) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.